Pathios Therapeutics Appoints Paul Higham As CEO Before Clinical Entry
09 Jul 2024 //
PR NEWSWIRE
Pathios Raises $25M Series B For First-In-Class Immunotherapy
18 Apr 2024 //
PR NEWSWIRE
Bristol Myers pitches in to Pathios’ $25M Series B for GPCR inhibitor
18 Apr 2024 //
ENDPTS
Pathios Awarded Innovate Grant to Evaluate First-in-Class Immunotherapy Approach
27 Sep 2023 //
PR NEWSWIRE
Pathios to Present Data Highlighting Potential of GPR65 Inhibition at SITC 2022
03 Nov 2022 //
PRNEWSWIRE
Pathios Therapeutics Presents Preclinical Data GPR65 inhibitor
07 Jul 2021 //
PR NEWSWIRE
Pathios Therapeutics Presents Preclinical In Vivo Proof of Concept Data
07 Jul 2021 //
PR NEWSWIRE
Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT
07 Jul 2021 //
PR NEWSWIRE
Pathios therapeutics receives £350K funding reward from Innovate UK
09 Mar 2021 //
BIOSPECTRUMASIA